Company Description

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.

The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.

It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.

Polyrizon Ltd.

Country	Israel
Founded	2005
IPO Date	Oct 29, 2024
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Tomer Izraeli

Contact Details

Address: 5 Ha-Tidhar Street Ra'anana, 4366507 Israel
Phone	972 5 5433 5665
Website	polyrizon-biotech.com

Stock Details

Ticker Symbol	PLRZ
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$4.38
CIK Code	0001893645
ISIN Number	IL0011814113
SIC Code	3841

Key Executives

Name	Position
Tomer Izraeli	Founder, Chief Executive Officer and Director
Nir Ben Yosef	Chief Financial Officer and Compliance Officer
Dr. Tidhar Turgeman	Chief Technology Officer
Dr. Eyal S. Ron Ph.D.	Chief Scientific Officer
Daphna Avital	Chief People Officer

Latest SEC Filings

Date	Type	Title
Mar 27, 2025	6-K	Report of foreign issuer
Mar 25, 2025	6-K	Report of foreign issuer
Mar 18, 2025	EFFECT	Notice of Effectiveness
Mar 14, 2025	6-K	Report of foreign issuer
Mar 13, 2025	6-K	Report of foreign issuer
Mar 11, 2025	POS AM	Post-Effective amendments for registration statement
Mar 11, 2025	20-F	Annual and transition report of foreign private issuers
Mar 10, 2025	6-K	Report of foreign issuer
Mar 5, 2025	SCHEDULE 13G	Filing
Jan 30, 2025	6-K	Report of foreign issuer

View All SEC Filings